STAT3 Pathway Targeting Type I Photosensitizer as an Immune Stimulator for Cancer Photoimmunotherapy

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Jingru Qiu, Qinghong Liu, Baolan Chen, Zhongfei Gao, Shuo Zhang, Yayin Du, Donghai Li*, Guiling Li* and Gang Shan*, 
{"title":"STAT3 Pathway Targeting Type I Photosensitizer as an Immune Stimulator for Cancer Photoimmunotherapy","authors":"Jingru Qiu,&nbsp;Qinghong Liu,&nbsp;Baolan Chen,&nbsp;Zhongfei Gao,&nbsp;Shuo Zhang,&nbsp;Yayin Du,&nbsp;Donghai Li*,&nbsp;Guiling Li* and Gang Shan*,&nbsp;","doi":"10.1021/acs.jmedchem.5c01062","DOIUrl":null,"url":null,"abstract":"<p >Signal transducer and activator of transcription 3 (STAT3) is broadly hyperactivated in cancer cells and plays an important role in regulating cell proliferation and immunosuppression. Inhibiting STAT3 can enhance T cell-mediated antitumor immunity. Inducing immunogenic cell death (ICD) via danger-associated molecular pattern release facilitates the migration and infiltration of T cells into tumors, making ICD induction combined with STAT3 inhibition a promising synergistic cancer therapy. In this work, we discovered that an old cationic carbocyanine dye <b>Stains-All</b> (<b>SA</b>) was a STAT3 pathway targeting type I photosensitizer. <b>SA</b> triggered immunogenic apoptosis and pyroptosis of tumor cells and provoked antitumor immune responses. Meanwhile, <b>SA</b> prevented tumor growth and blocked immune escape by inhibiting STAT3 activation. Moreover, efficient ICD induction and STAT3 inhibition synergistically suppressed the growth of both primary and distant tumors. Overall, this study repurposed <b>SA</b> as a novel photoimmune stimulator targeting the STAT3 pathway for the synergistic tumor ablation.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 15","pages":"16103–16113"},"PeriodicalIF":6.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01062","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Signal transducer and activator of transcription 3 (STAT3) is broadly hyperactivated in cancer cells and plays an important role in regulating cell proliferation and immunosuppression. Inhibiting STAT3 can enhance T cell-mediated antitumor immunity. Inducing immunogenic cell death (ICD) via danger-associated molecular pattern release facilitates the migration and infiltration of T cells into tumors, making ICD induction combined with STAT3 inhibition a promising synergistic cancer therapy. In this work, we discovered that an old cationic carbocyanine dye Stains-All (SA) was a STAT3 pathway targeting type I photosensitizer. SA triggered immunogenic apoptosis and pyroptosis of tumor cells and provoked antitumor immune responses. Meanwhile, SA prevented tumor growth and blocked immune escape by inhibiting STAT3 activation. Moreover, efficient ICD induction and STAT3 inhibition synergistically suppressed the growth of both primary and distant tumors. Overall, this study repurposed SA as a novel photoimmune stimulator targeting the STAT3 pathway for the synergistic tumor ablation.

Abstract Image

STAT3通路靶向I型光敏剂作为肿瘤光免疫治疗的免疫刺激剂。
STAT3在肿瘤细胞中广泛高激活,在调节细胞增殖和免疫抑制中起重要作用。抑制STAT3可增强T细胞介导的抗肿瘤免疫。通过危险相关的分子模式释放诱导免疫原性细胞死亡(ICD)促进T细胞向肿瘤的迁移和浸润,使ICD诱导联合STAT3抑制成为一种有前景的协同癌症治疗方法。在这项工作中,我们发现一种古老的阳离子碳菁染料Stains-All (SA)是STAT3途径靶向I型光敏剂。SA诱导肿瘤细胞免疫原性凋亡和焦亡,引起抗肿瘤免疫应答。同时,SA通过抑制STAT3的激活,抑制肿瘤生长,阻断免疫逃逸。此外,有效的ICD诱导和STAT3抑制协同抑制原发和远处肿瘤的生长。总的来说,本研究将SA作为一种靶向STAT3通路的新型光免疫刺激剂用于协同肿瘤消融。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信